Sudhir Agrawal to Humans
This is a "connection" page, showing publications Sudhir Agrawal has written about Humans.
Connection Strength
0.321
-
Agrawal S. RNA Therapeutics Are Stepping Out of the Maze. Trends Mol Med. 2020 12; 26(12):1061-1064.
Score: 0.028
-
Kandimalla ER, Bhagat L, Wang D, Yu D, Sullivan T, La Monica N, Agrawal S. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res. 2013 Apr 01; 41(6):3947-61.
Score: 0.016
-
Lan T, Wang D, Bhagat L, Philbin VJ, Yu D, Tang JX, Putta MR, Sullivan T, La Monica N, Kandimalla ER, Agrawal S. Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo. Org Biomol Chem. 2013 Feb 14; 11(6):1049-58.
Score: 0.016
-
Bhagat L, Putta MR, Wang D, Yu D, Lan T, Jiang W, Sun Z, Wang H, Tang JX, La Monica N, Kandimalla ER, Agrawal S. Novel oligonucleotides containing two 3'-ends complementary to target mRNA show optimal gene-silencing activity. J Med Chem. 2011 Apr 28; 54(8):3027-36.
Score: 0.014
-
Putta MR, Zhu FG, Wang D, Bhagat L, Dai M, Kandimalla ER, Agrawal S. Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity. Bioconjug Chem. 2010 Jan; 21(1):39-45.
Score: 0.013
-
Lan T, Dai M, Wang D, Zhu FG, Kandimalla ER, Agrawal S. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies. J Med Chem. 2009 Nov 12; 52(21):6871-9.
Score: 0.013
-
Yu D, Wang D, Zhu FG, Bhagat L, Dai M, Kandimalla ER, Agrawal S. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J Med Chem. 2009 Aug 27; 52(16):5108-14.
Score: 0.013
-
Lan T, Putta MR, Wang D, Dai M, Yu D, Kandimalla ER, Agrawal S. Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8. Biochem Biophys Res Commun. 2009 Aug 28; 386(3):443-8.
Score: 0.013
-
Lan T, Bhagat L, Wang D, Dai M, Kandimalla ER, Agrawal S. Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8. Bioorg Med Chem Lett. 2009 Apr 01; 19(7):2044-7.
Score: 0.012
-
Wang D, Bhagat L, Yu D, Zhu FG, Tang JX, Kandimalla ER, Agrawal S. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. J Med Chem. 2009 Jan 22; 52(2):551-8.
Score: 0.012
-
Yu D, Putta MR, Bhagat L, Dai M, Wang D, Trombino AF, Sullivan T, Kandimalla ER, Agrawal S. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction. Antimicrob Agents Chemother. 2008 Dec; 52(12):4320-5.
Score: 0.012
-
Yu D, Putta MR, Bhagat L, Li Y, Zhu F, Wang D, Tang JX, Kandimalla ER, Agrawal S. Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs. J Med Chem. 2007 Dec 13; 50(25):6411-8.
Score: 0.011
-
Lan T, Kandimalla ER, Yu D, Bhagat L, Li Y, Wang D, Zhu F, Tang JX, Putta MR, Cong Y, Trombino AF, Sullivan T, Agrawal S. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc Natl Acad Sci U S A. 2007 Aug 21; 104(34):13750-5.
Score: 0.011
-
Putta MR, Zhu F, Li Y, Bhagat L, Cong Y, Kandimalla ER, Agrawal S. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications. Nucleic Acids Res. 2006; 34(11):3231-8.
Score: 0.010
-
Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong YP, Song SS, Tang JX, Sullivan T, Agrawal S. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci U S A. 2005 May 10; 102(19):6925-30.
Score: 0.010
-
Agrawal S, Kandimalla ER. Role of Toll-like receptors in antisense and siRNA [corrected]. Nat Biotechnol. 2004 Dec; 22(12):1533-7.
Score: 0.009
-
Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int J Oncol. 2004 Apr; 24(4):901-8.
Score: 0.009
-
Agrawal S, Kandimalla ER. Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA. Ann N Y Acad Sci. 2003 Dec; 1002:30-42.
Score: 0.009
-
Kandimalla ER, Bhagat L, Zhu FG, Yu D, Cong YP, Wang D, Tang JX, Tang JY, Knetter CF, Lien E, Agrawal S. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A. 2003 Nov 25; 100(24):14303-8.
Score: 0.009
-
Cong YP, Song SS, Bhagat L, Pandey RK, Yu D, Kandimalla ER, Agrawal S. Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells. Biochem Biophys Res Commun. 2003 Oct 31; 310(4):1133-9.
Score: 0.009
-
Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, Tang J, Wang H, Huang P, Zhang R, Agrawal S. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 2003 May 01; 31(9):2393-400.
Score: 0.008
-
Bhagat L, Zhu FG, Yu D, Tang J, Wang H, Kandimalla ER, Zhang R, Agrawal S. CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun. 2003 Jan 24; 300(4):853-61.
Score: 0.008
-
Agrawal S, Kandimalla ER, Yu D, Ball R, Lombardi G, Lucas T, Dexter DL, Hollister BA, Chen SF. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int J Oncol. 2002 Jul; 21(1):65-72.
Score: 0.008
-
Agrawal S, Kandimalla ER. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 2002 Mar; 8(3):114-21.
Score: 0.008
-
Pelka K, Phulphagar K, Zimmermann J, Stahl R, Schmid-Burgk JL, Schmidt T, Spille JH, Labzin LI, Agrawal S, Kandimalla ER, Casanova JL, Hornung V, Marshak-Rothstein A, H?ning S, Latz E. Cutting edge: the UNC93B1 tyrosine-based motif regulates trafficking and TLR responses via separate mechanisms. J Immunol. 2014 Oct 01; 193(7):3257-61.
Score: 0.005
-
Henriques-Pons A, Yu Q, Rayavarapu S, Cohen TV, Ampong B, Cha HJ, Jahnke V, Van der Meulen J, Wang D, Jiang W, Kandimalla ER, Agrawal S, Spurney CF, Nagaraju K. Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Hum Mol Genet. 2014 May 15; 23(10):2604-17.
Score: 0.004
-
Zhang H, Liu L, Yu D, Kandimalla ER, Sun HB, Agrawal S, Guha C. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PLoS One. 2012; 7(5):e38111.
Score: 0.004
-
Kandimalla ER, Struthers M, Bett AJ, Wisniewski T, Dubey SA, Jiang W, Precopio M, Sun Z, Wang H, Lan T, Agrawal S, Casimiro DR. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists. Cell Immunol. 2011; 270(2):126-34.
Score: 0.004
-
Struthers M, Bett AJ, Wisniewski T, Dubey SA, Precopio M, Jiang W, Sun Z, Wang H, Nowak I, Putta MR, Yu D, Tang JX, Kandimalla ER, Agrawal S, Casimiro DR. Synthesis and immunological activities of novel agonists of toll-like receptor 9. Cell Immunol. 2010; 263(1):105-13.
Score: 0.003
-
Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res. 2009 Nov 15; 15(22):6921-30.
Score: 0.003
-
Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla ER, Agrawal S, Ciardiello F, Tortora G. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A. 2007 Jul 24; 104(30):12468-73.
Score: 0.003
-
LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res. 2006 Sep 01; 12(17):5231-41.
Score: 0.003
-
Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther. 2006 Aug; 5(8):2106-14.
Score: 0.003
-
Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther. 2006 Jun; 5(6):1585-92.
Score: 0.003
-
Lacasse EC, Kandimalla ER, Winocour P, Sullivan T, Agrawal S, Gillard JW, Durkin J. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640. Ann N Y Acad Sci. 2005 Nov; 1058:215-34.
Score: 0.002
-
McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, Morris SJ, Durkin JP, Lacasse EC. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene. 2004 Oct 21; 23(49):8105-17.
Score: 0.002
-
Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol. 2002 Jul; 21(1):73-80.
Score: 0.002